TY - JOUR ID - 16874 TI - An Endogenous Immune Adjuvant Released by Necrotic Cells for Enhancement of DNA Vaccine Potency JO - Iranian Journal of Immunology JA - IJI LA - en SN - 1735-1383 AU - Dorostkar, Rohollah AU - Bamdad, Taravat AU - Parsania, Masoud AU - Pouriayevali, Hassan AD - Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran AD - Department of Microbiology, Tehran Medical Branch, Islamic Azad University, Tehran, Iran Y1 - 2012 PY - 2012 VL - 9 IS - 4 SP - 215 EP - 225 KW - Adjuvant KW - DNA vaccine KW - Herpes Simplex Virus-1 KW - Necrosis DO - N2 - Background: Improving vaccine potency in the induction of a strong cell-mediated cytotoxicity can enhance the efficacy of vaccines. Necrotic cells and the supernatant of necrotic tumor cells are attractive adjuvants, on account of their ability to recruit antigen-presenting cells to the site of antigen synthesis as well as its ability to stimulate the maturation of dendritic cells. Objective: To evaluate the utility of supernatant of necrotic tumor cells as a DNA vaccine adjuvant in a murine model. Method: The supernatant of EL4 necrotic cells was co-administered with a DNA vaccine expressing the glycoprotein B of Herpes simplex virus-1 as an antigen model under the control of Cytomegalovirus promoter. C57BL/6 mice were vaccinated three times at two weeks intervals with glycoprotein B DNA vaccine and supernatant of necrotic EL4 cells. Five days after the last immunization, cell cytotoxicity, IFN-γ and IL-4 were evaluated. Results: The obtained data showed that the production of IFN-γ from the splenocytes after antigenic stimulation in the presence of the supernatant of necrotic EL4 cells was significantly higher than the other groups (p<0.002). The flow cytometry results showed a significant increase in the apoptosis/necrosis of EL4 cells in the mice immunized with DNA vaccine and supernatant of necrotic EL4 cells comparing to the other groups (p<0.001). Conclusion: The supernatant of necrotic cells contains adjuvant properties that can be considered as a candidate for tumor vaccination. UR - https://iji.sums.ac.ir/article_16874.html L1 - https://iji.sums.ac.ir/article_16874_18109a6f4be2028aebd57581d180f3b0.pdf ER -